Parenteral glutamine supplementation in critical illness: a systematic review by unknown
Wischmeyer et al. Critical Care 2014, 18:R76
http://ccforum.com/content/18/2/R76RESEARCH Open AccessParenteral glutamine supplementation in critical
illness: a systematic review
Paul E Wischmeyer1*, Rupinder Dhaliwal2, Michele McCall3, Thomas R Ziegler4 and Daren K Heyland2,5Abstract
Introduction: The potential benefit of parenteral glutamine (GLN) supplementation has been one of the
most commonly studied nutritional interventions in the critical care setting. The aim of this systematic review
was to incorporate recent trials of traditional parenteral GLN supplementation in critical illness with previously
existing data.
Methods: All randomized controlled trials of parenterally administered GLN in critically ill patients conducted from
1997 to 2013 were identified. Studies of enteral GLN only or combined enteral/parenteral GLN were excluded.
Methodological quality of studies was scored and data was abstracted by independent reviewers.
Results: A total of 26 studies involving 2,484 patients examining only parenteral GLN supplementation of nutrition
support were identified in ICU patients. Parenteral GLN supplementation was associated with a trend towards a
reduction of overall mortality (relative risk (RR) 0.88, 95% confidence interval (CI) 0.75, 1.03, P = 0.10) and a significant
reduction in hospital mortality (RR 0.68, 95% CI 0.51, 0.90, P = 0.008). In addition, parenteral GLN was associated with
a strong trend towards a reduction in infectious complications (RR 0.86, 95% CI 0.73, 1.02, P = 0.09) and ICU length
of stay (LOS) (WMD –1.91, (95% CI −4.10, 0.28, P = 0.09) and significant reduction in hospital LOS (WMD −2.56,
95% CI −4.71, −0.42, P = 0.02). In the subset of studies examining patients receiving parenteral nutrition (PN),
parenteral GLN supplementation was associated with a trend towards reduced overall mortality (RR 0.84, 95% CI
0.71, 1.01, P = 0.07).
Conclusions: Parenteral GLN supplementation given in conjunction with nutrition support continues to be
associated with a significant reduction in hospital mortality and hospital LOS. Parenteral GLN supplementation as a
component of nutrition support should continue to be considered to improve outcomes in critically ill patients.Introduction
Glutamine (GLN) is the most abundant nonessential free
amino acid [1] and has traditionally been classified as a
nonessential amino acid able to be synthesized de novo
in states of health. Glutamine is now commonly described
as a conditionally essential amino acid, particularly in
catabolic and stress states [2]. In catabolic states, large
amounts of GLN are released from muscle tissue [3] as
part of the body’s conserved evolutionary response to
stress. Previous explanations for the release of GLN in
periods of stress include use as a fuel source for rapidly
dividing cells, a precursor for synthesis of nucleic acids,
and a role in renal acid buffering [4,5]. Recent data has* Correspondence: Paul.Wischmeyer@ucdenver.edu
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distribution, and reproduction in any mediumrevealed that following illness and injury, GLN plays a vital
role in inducing cellular protection pathways, modulation
of the inflammatory response, and prevention of organ
injury [1]. Contrary to long-held beliefs, not all critically ill
patients become markedly deficient in the first few days of
ICU admission, although some will present with severe
depletion, such as is consistently seen in burn patients
[6-8]. Recent data has shown GLN becomes depleted in
approximately 25 to 35% of ICU patients at admission to
ICU [6-8]. Patients with more prolonged critical illness,
and in some studies, those receiving parenteral nutrition
(PN) have shown show a greater level of depletion as
described in a number of trials of PN-requiring ICU
patients [9,10]. When GLN depletion is present at ad-
mission to ICU, it has been associated with increased
mortality [7,8]. Clinical trials from the past 20 years dem-
onstrated that GLN appears to reduce mortality, infectiousntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Most of these previous trials were conducted in a select
group of patients with the following characteristics: 1)
predominantly receiving complete nutrition support via
PN, 2) common exclusion of renal and liver failure based
on glutamine product prescribing restrictions, 3) GLN
supplementation of PN is often initiated later in the ICU
stay (not at ICU admission during the shock phase), as
PN is typically started later in the stay when enteral nutri-
tion (EN) is not possible or meeting nutritional needs, 4)
enrollment of oncology patients who may be at a greater
risk for tumor-mediated GLN depletion, 5) use of GLN
dose between 0.3 g/kg/day to a maximum of 0.5 g.kg/day
given only via the intravenous route. This is summarized
below:
Characteristics of traditional parenteral glutamine-
supplementation trials
1. Enrolled patients requiring parenteral nutrition in
most trials (85% of published trials)
2. Glutamine given as a supplement to nutrition
support - not as a separate pharmaconutrient
independent of nutrition support
3. GLN supplementation given with the start of PN
later in the ICU stay, often when EN was not
possible or failing to meet nutritional needs.
(Not typically at ICU admission)
4. Common exclusion of renal and liver failure based
on glutamine product prescribing restrictions
(See Table 1 for specific trial exclusion criteria)
5. Lower GLN doses (0.3 to 0.5 g/kg/day)
6. Combined enteral and parenteral GLN not given
Recently, a new paradigm of pharmacological GLN
administration was tested in a large multicenter clinical
trial utilizing a combined enteral and intravenous dose
of GLN, which averaged between 0.6 to 0.8 g/kg/day
independent of the administration of complete nutrition
[6]. This study, the REDOXS study, also primarily en-
rolled patients who, as defined by the inclusion criteria,
were required to be in multi-system organ failure within
24 hours of admission. Finally, renal failure and acute
liver failure were, for the first time, not excluded and in
fact, more than 30% of the patients in REDOXS pre-
sented with baseline acute renal failure. The results of
this trial surprisingly showed contrary to many previous
traditional PN-based GLN trials, that GLN supplementa-
tion was associated with an increase in mortality.
Thus, a key question to be answered is whether paren-
teral GLN administered as a supplement to complete nutri-
tion support (for example via PN) is beneficial or harmful.
This question is timely given the large number of (n = 11)
of randomized clinical trials of GLN supplementation
of PN published since 2009. Recently a number of meta-analysis have been published examining the use of GLN in
burn injury, pancreatitis, and surgical and critical illness
combined [11-14], however a systematic analysis focused
on parenteral GLN supplementation in critical illness has
not been performed. Further, these past meta-analysis
have not incorporated all of the most recently available
trial data. The aim of this current systematic literature
review and meta-analysis is to focus on the question of
whether the ‘traditional’ parenteral administration of GLN
as part of nutrition support has an effect on relevant
clinical outcomes in patients classified with critical illness
(as opposed to elective surgery or only single diagnosis
groups, such as burn injury).
Methods
Study identification
The following databases were searched for articles from
1980 until July 2013: EMBASE, MEDLINE, CINAHL
and the Cochrane Controlled Trials Register and Data-
base of Systematic Reviews. The literature search used
broad search terms containing ‘randomized’, ‘blind’,
‘clinical trial’, ‘nutrition’, ‘nutritional support’ or ‘dietary
supplementation’ or ‘enteral nutrition’ or ‘parenteral nu-
trition’ or ‘parenteral nutrition solutions’ and ‘critical care’
or ‘critical illness’ or ‘intensive care units’. The results were
then reviewed to identify articles using parenteral or
intravenous GLN supplementation. A unique feature
of this meta-analysis is that no language restrictions
were placed on the searches. Personal files and reference
lists of relevant review articles were also reviewed. As this
was a systematic review no ethics board approval or
patient consent was required.
Study selection criteria
We only included original studies if they met the following
inclusion criteria: a) study design: randomized clinical
trials, b) population: critically ill adult patients (>18 years
of age), defined as patients admitted to an ICU. When this
was unclear, we considered a mortality rate higher than
5% (hospital mortality and if this was not reported we
used ICU mortality or 28-day mortality) in the control
group to be consistent with critical illness, c) intervention:
parenteral GLN versus control (either isonitrogenous
amino acid control) or placebo, d) study outcomes: must
have included one of the following: mortality, ICU and
hospital LOS, infectious complications, and other clinic-
ally important complications. Studies of enteral GLN only
or combined enteral/parenteral GLN were excluded).
Data abstraction
Decisions about the inclusion of the articles were made
in duplicate. All original studies were reviewed independ-
ently by two reviewers using a data abstraction form with
a scoring system as shown in Table 2. An assessment of
Table 1 Randomized studies evaluating glutamine (PN) in critically ill patients
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ICU 17.5 ± 14.6 (75).
Hospital 33.6 ± 28 (75)
ICU 13.6 ± 10
(75). Hospital
29.7 ± 20.7 (75)
†Hospital mortality unless stated otherwise; ‡number of patients with infections unless stated otherwise; *data for length of stay is in median and ranges; **data for mortality is ITT, infections is non-ITT; ∂data from growth hormone
group not shown here. ± ( ), mean ± standard deviation (number); Compl, complications; ICU, intensive care unit; Infec/pt, infections per patient; C.Random, concealed randomization median (range); Pneu, pneumonia; PN, parenteral
nutrition; ITT, intention to treat; EN, enteral nutrition; TPN, total parenteral nutrition; NR, not reported; FOS, fructooligosaccharides; MODS, multiple organ dysfunction syndrome; CHI, closed head injury; GCS, Glasgow Coma
Scale; APACHE II, Acute Physiology and Chronic Health Evaluation II; ISS, injury severity score; Vent days, ventilator days; VAP, ventilator-associated pneumonia; ASPEN, American Society for Parenteral and Enteral Nutrition;














Table 2 Randomized trial quality scoring system
Score
0 1 2
Randomization … Not concealed or not sure Concealed randomization
Analysis Other … Intention-to-treat
Blinding Not blinded Single-blind Double-blinded
Patient selection Selected patients or unable to tell Consecutive eligible patients …..
Comparability of groups at baseline No or not sure Yes ….
Extent of follow-up <100% 100% ….
Treatment protocol Poorly described Reproducibly described ….
Co-interventions Not described Described but not equal or not sure Well described and all equal
Outcomes Not described Partially described Objectively defined
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intervention and control/placebo and clinical outcomes
were made as per earlier publications [15]. The metho-
dological quality of individual trials was also assessed
according to a) whether randomization was concealed, b)
blinding, c) analysis was based on the intention-to-treat
(ITT) principle, d) patient selection, e) comparability of
groups at baseline, f ) extent of follow-up, g) description of
treatment protocol and co-interventions, and h) definition
of clinical outcomes. Each individual study was scored
from 1 to 14 (Table 2). Disagreement in the individual
scores of each of the categories was resolved by consensus
between both reviewers. We attempted to contact the
authors of included studies and requested additional
information not contained in published articles.
Data synthesis
The primary outcome of the systematic review was overall
mortality. From all studies, we combined hospital mortal-
ity where reported (specified or assumed to be hospital if
not specified). If hospital mortality was not reported, we
used ICU mortality or, if ICU mortality was not reported,
we used 28-day mortality. Secondary outcomes inclu-
ded infection, ventilator-associated pneumonia (VAP),
and ICU and hospital LOS. We used definitions of infec-
tions as defined by the authors in their original articles.
We combined data from all trials to estimate the pooled
risk ratio (RR) with 95% confidence intervals (CIs) for
mortality, infectious complications, VAP and overall
weighted mean difference (WMD) with 95% CIs for
LOS data. Pooled RRs were calculated using the Mantel-
Haenszel estimator and WMDs were estimated by the
inverse variance approach. The random effects model of
Der Simonian and Laird was used to estimate variances
for the Mantel-Haenszel and inverse variance estimators
[16]. All analyses, except the test for asymmetry, were
conducted using Review Manager (RevMan) 5.1 software.
(The Nordic Cochrane Centre, The Cochrane Collabor-
ation, Copenhagen, Denmark, 2011) [17].When possible, studies were aggregated on an ITT
basis (Table 2). The presence of heterogeneity was tested
by a weighted Mantel-Haenszel chi-square test and
quantified by the I2 statistic as implemented in RevMan
5.1 [17,18]. The possibility of publication bias was assessed
by generating funnel plots and testing asymmetry of out-
comes using methods proposed by Rucker and colleagues
[19]. We considered P <0.05 to be statistically significant
and P <0.20 as the indicator of trend.
Subgroup analyses
We utilized predefined subgroup analysis to assess a
number of possible influences on the effect of parenteral
GLN supplementation on clinical outcomes. We first
examined the effect of parenteral GLN supplementation
of PN versus EN alone. As trials examining EN alone
consistently deliver significantly less total overall energy
and protein delivery, we hypothesized that parenteral
GLN may have a different effect when complete nutrition
support was being given via EN alone or as a component
of PN delivery. We next assessed the effect of trial quality
on outcome as it is often hypothesized trials of lower
methodological quality tend to yield more positive clinical
signals for the therapy being tested when compared to
trials of higher methodological quality. Utilizing our trial
scoring tool, we designated trials with a methodological
score of >8 as a ‘high-quality trial’ for the purposes of this
review. Finally, it has been postulated that single-center
trials may yield a greater chance of a positive clinical
signal versus more rigorous multi-center trials [16],
thus we examined the effect of these two types of trials on
our clinical outcomes.
Results
Study identification and selection
The literature search yielded 58 potentially eligible
randomized controlled trials of which 26 were included in
our systematic review. As shown in Table S1 in Additional
file 1, a total of 32 studies were excluded for these reasons:
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clinical outcomes (n = 5), 3) were duplicate studies or
subgroups of included studies (n = 3), 4) crossover design
studies (n = 2), 5) varying doses of GLN (n = 1), 6) a trial
of combined enteral and parenteral GLN (n = 1), 7) ques-
tionably low dosage of GLN (0.002 g/kg/day) (n = 1, see
Table S1 in Additional file 1) and 8) one trial reported data
from a subgroup of its total study population [10], see
Table S1 in Additional file 1).
Thus, we included 26 studies of parenteral GLN sup-
plementation performed in ICU patients with diagnosis
ranging from pancreatitis, trauma, burns to sepsis descri-
bed in Table 1 [9,15,20-44]. While in the majority of the
studies, the intervention and control groups received
GLN-free parenteral nutrition/amino acids, in four studies,
patients received only EN as the sole source of nutrition
support [23,31-33].
Meta-analyses of primary and secondary outcomes
Effect of GLN supplementation on mortality
When the 24 studies that reported on mortality (Figure 1)
were aggregated, IV GLN supplementation was associ-
ated with a trend towards a reduction in overall mortality
(RR 0.88, 95% CI 0.75, 1.03, P = 0.10, heterogeneity I2 = 0%).Figure 1 Overall mortality.In the 13 studies (Figure 2) that reported hospital mortality,
a significant reduction in hospital mortality was seen when
they were aggregated (RR 0.68, 95% CI 0.51, 0.90, P = 0.008,
heterogeneity I2 = 0%).
Effect of GLN supplementation on infectious complications,
ICU length of stay and hospital length of stay
When the 12 studies (Figure 3), which reported infec-
tious complications, were aggregated, GLN supplemen-
tation was associated with a trend towards a reduction
in infectious complications (RR 0.86, 95% CI 0.73, 1.02,
P = 0.09, heterogeneity I2 = 43%). When the six studies
that reported VAP (Figure 4) were aggregated, GLN
supplementation was associated with a trend towards
a reduction in pneumonia (RR 0.76, 95% CI 0.56, 1.04,
P = 0.09, heterogeneity I2 = 0%).
When the 11 studies that reported ICU length of
stay as a mean ± standard deviation were aggregated
(Figure 5), GLN supplementation was associated with
a trend to reduction in ICU LOS (WMD −1.91, 95%
CI −4.10, −0.28, P = 0.09, heterogeneity I2 = 90%). Fi-
nally, when the 11 studies reporting on hospital LOS were
aggregated (Figure 6), GLN supplementation was asso-
ciated with a significant reduction in hospital LOS
Figure 2 Hospital mortality.
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geneity I2 = 63%).
Subgroup analysis
Results across all these subgroups are reported in
Table 3. Overall tests for significance between subgroups
revealed no statistically significant differences between
any individual subgroups.
Effect of parenteral GLN supplementation of PN versus
EN alone
Examining the effect of GLN supplementation of PN
versus EN alone, the test for subgroup differences in
overall mortality outcomes was not significant (P = 0.66).
In the studies in which patients received intravenous
(IV) GLN plus PN, GLN supplementation was associated
with a trend towards a reduction in overall mortality (RRFigure 3 Infectious complications.0.84, 95% CI 0.71, 1.01, P = 0.07, heterogeneity I2 = 3%;
Figure 1, Table 3). Only four studies reported on
mortality for GLN supplementation of EN. When the
studies in which patients only received IV GLN and
EN [23,31-33] were aggregated, GLN supplementation
had no effect on overall mortality (RR 0.94, 95% CI 0.61,
1.47, P = 0.79, heterogeneity I2 = 0%; Figure 1, Table 3). In
the subgroup of studies in which patients received IV
GLN plus PN, GLN supplementation had no effect on
infectious complications (RR 0.89, 95% CI 0.74, 1.06,
P = 0.20, heterogeneity I2 = 48%; Figure 3, Table 3).
However, for the subgroup of studies in which patients
received IV GLN and were on EN alone [23,33], GLN
supplementation was associated with a trend towards a
reduction in infectious complications (RR 0.68, 95%
CI 0.45, 1.05, P = 0.08, heterogeneity I2 = 0%; Figure 3,
Table 3). The test for subgroup differences in infectious
Figure 4 Ventilator-associated pneumonia.
Wischmeyer et al. Critical Care 2014, 18:R76 Page 9 of 17
http://ccforum.com/content/18/2/R76morbidity overall in EN alone versus PN studies was not
significant (P = 0.27).
For the subgroup of studies in which patients received
IV GLN plus PN, GLN supplementation was not associ-
ated with a reduction in ICU LOS. Similarly no effect on
ICU LOS was observed in patients receiving only EN
that received IV GLN [23,31-33]. The test for sub-
group differences in ICU LOS overall was not significant
(P = 0.42). None of the studies in which patients only
received EN reported on hospital LOS and therefore no
subgroup analyses were done.
Effect of study quality on outcomes
Higher quality trials (methodological score of >8) showed
a stronger statistical trend towards reduced mortalityFigure 5 ICU length of stay.than trials of lower quality (P = 0.12 versus P = 0.49
respectively), although the effect size was similar be-
tween the groups (Table 3). The overall test for sub-
group difference was not significant for these subgroups
(P = 0.79).
A statistically significant effect for GLN reducing hos-
pital mortality was only seen in the higher quality trials,
although there were a smaller number of patients enrolled
in the lower quality trials and this reduced the statistical
power of the signal (Table 3). Again, overall tests for sig-
nificance did not reveal statistically significant differences
between these subgroups (P = 0.21). There were insuffi-
cient numbers of trials reporting on infectious outcomes
and LOS data in the low- and high-quality categories to
allow for these comparisons to be made.
Figure 6 Hospital length of stay.
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The role of multi-center versus single center trials
revealed that only the single center trials demonstrated a
significant effect of GLN on overall and hospital mortal-
ity and infectious outcomes (Table 3). Only the multi-
center trials demonstrated a significant benefit of GLN
on the incidence of VAP (Table 3). Overall tests for
significance did not reveal statistically significant dif-
ferences between these subgroups. (P = 0.45 for mortal-
ity and P = 0.16 for infectious morbidity, and P = 0.34
for VAP).
Risk of bias across studies
Funnel plots for all outcomes were created to assess for
publication bias as shown in Figure 7. The test of
asymmetry was not found to be significant for any of the
endpoints including overall mortality (P = 0.57), hospital
mortality (P = 0.86), infectious complications (P = 0.05)
ICU LOS (0.87), or hospital LOS (0.69).
Discussion
Meta-analysis of the initial randomized controlled trials
of parenteral GLN supplementation suggested outcome
benefits in the six early trials examining critical illness
[45]. Since that time an additional 22 randomized clinical
trials have been performed in over 2,000 patients receiving
GLN as a component of complete nutrition support, pri-
marily given as PN (85% of trials). In addition, we have a
much greater understanding of the potential beneficial
mechanisms of GLN in critical illness as summarized in
recent reviews [1,46].
Early trials of GLN were primarily focused on patients
receiving full nutrition support primarily by PN at doses
falling within the approved prescribing indications for
dose in commercially available GLN preparations. Fur-
ther, as shown in Table 1, patients in these traditional
trials were commonly excluded from enrollment if they
had pre-existing renal or liver failure. These traditional
nutritionally oriented (or non-pharmaconutrition based)
GLN supplementation trials have shown a consistent
reduction of mortality and benefit on other outcomes assuggested by the 2009 update of the Canadian Critical
Care Nutrition Guidelines [47]. However, given the publi-
cation of 11 new randomized controlled trials examining
the traditional parenteral use of GLN as a component of
nutrition support (predominantly PN) since 2009, a new
systematic review is indicated.
This need for a new systematic review is further driven
by the results of the REDOXS trial, a 1,200-patient,
40-center randomized controlled trial of ‘pharmacologic-
ally dosed’ parenteral and enteral GLN (approximately 0.6
to 0.8 g/kg/day) factorialized with antioxidant supple-
mentation [6]. This trial was distinct from any of the pre-
viously published parenteral GLN trials supplementing
PN or EN in ICU patients as GLN (and a cocktail of anti-
oxidants) were administered independent of any concomi-
tant nutrition support. In contrast to the design of studies
reported in this analysis, the nutritional delivery of energy
and protein in the REDOXS trial averaged less than 50%
of that prescribed for the patient, and thus was quite
insufficient in meeting patient needs. In addition, all pa-
tients in the REDOXS trial had documented multi-system
organ failure at enrollment, which is a common exclusion
criteria in the trials reported in this analysis using paren-
teral GLN as a supplement to nutrition support. Further,
more than 30% of REDOXS patients were found to have
baseline renal failure at admission, which was a very com-
mon exclusion criteria in the trials reported in the analysis
(Table 1). As stated, this is a key difference of REDOXS
from all other GLN trials.
Thus, given the many differences in fundamental trial
design between REDOXS and traditional GLN supple-
mentation trials, the REDOXS trial has not been included
in this systematic review focused on GLN supplemen-
tation of nutrition support. However, the publication
of the REDOXS trial necessitates a close examination
of the many new GLN supplementation trials pub-
lished recently to examine if there has been a change
in the fundamental signal of benefit of GLN supple-
mentation of PN seen in historical trials in the recent
era of critical care practice. This was the primary aim
of this systematic review.
Table 3 Subgroup analyses



































5 214 0.81 (0.44, 1.48),
P = 0.49
P = 0.79 3 134 0.26 (0.06, 1.19),
P = 0.08
P = 0.21 NA
High quality
(≥8)
19 2103 0.88 (0.74, 1.04)
P = 0.12






19 1011 0.75 (0.60, 0.93),
P = 0.009
P = 0.04 11 603 0.64 (0.47, 0.88),
P = 0.006
P = 0.45 8 371 0.77 (0.60, 0.98),
P = 0.03
P = 0.16
Multi-center 5 1306 1.03 (0.83,1.28)
P = 0.79
2 264 0.86 (0.43, 1.71),
P = 0.67





20 2128 0.84 (0.71, 1.01)
P = 0.07





4 184 0.94 (0.61, 1.47),
P = 0.79























Effect on ICU LOS












Low quality (<8) NA NA
High quality (≥8)
Number of sites
Single center NA 4 226 0.86 (0.58, 1.28),
P = 0.45
P = 0.34
Multi-center 2 264 0.63 (0.38, 1.04)
P = 0.07
PN vs. EN
Patients on PN 8 354 −2.30 (−6.50, 1.90) P = 0.28 P = 0.42 4 366 0.79 (0.57, 1.09)
P = 0.16
P = 0.40
Patients on EN 3 184 −0.47 (−1.84, 0.90) P = 0.50 2 124 0.44 (0.11, 1.67),
P = 0.23















Figure 7 Funnel plots of primary and secondary outcomes. (A) Overall mortality: (Test for asymmetry p=0.57); (B) hospital mortality:
(Test for asymmetry p=0.86); (C) infection: (Test for asymmetry p=0.05); (D) ICU LOS: (Test for asymmetry p=0.87); (E) hospital LOS: (Test for
asymmetry p=0.69). LOS, length of stay.
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continues to show a significant reduction in hospital
mortality. In addition, GLN supplementation of com-
plete nutrition was found to be associated with a strong
trend towards a reduction in infectious complications,
ICU LOS and a significant reduction in hospital LOS.
GLN supplementation as part of nutrition support also
continues to show a trend towards reduction of overall
mortality in all trials examining both PN and EN nutri-
tion delivery. The signal may be stronger for trials that
utilize GLN supplementation as part of PN nutrition
delivery. Importantly, no statistically significant signal of
publication bias was observed in any of our tests for
asymmetry as shown in the funnel plots in Figure 7.
A number of high-quality multi-center trials of paren-
teral GLN supplementation have been published recently,
driving the need for this new critical care focused system-
atic review. A number of these key trials have strengths
and weaknesses that are in some cases not reflected in the
trial quality scoring utilized by this and other systematic
reviews. Thus, a brief discussion of some of these key trials
is useful. In short, these trials include the Scandinavian
GLN trial [39], which examined 413 patients in multiple
centers and demonstrated a benefit on ICU survival rates
with parenteral GLN. A limitation of this trial was that it
was stopped prior to achievement of its predefined enroll-
ment goal due to slow enrollment. Another multi-center
trial, the SIGNET trial, showed no benefit of short-term
(approximately ≤4 days), low-dose GLN (approximately
0.2 g/kg/d) given parenterally to ICU patients on paren-
teral feeding [20]. Some concerns with this trial included
lack of availability of some key data including issues
regarding missing values, dropouts, protocol violations,
and complete follow-up data. The actual values for GLN
doses based on body weight have not been published and
this has been viewed as a significant limitation of the trial.
In an attempt to address the effect of quality of the trials
and single-center versus multi-center trials included in
the systematic review, we performed subgroup analyses to
examine the role of these factors. We observed a more
significant signal for parenteral GLN supplementation
reducing mortality in the higher quality studies versus the
lower quality trials. Single-center trials showed a greater
benefit of GLN supplementation on mortality and overall
infectious morbidity, although no signals of harm were
observed in the multi-center trials of GLN on mortality.
Interestingly, the beneficial effect of GLN on VAP was
greater in the multi-center trials then the single-center
trials. This is an endpoint that may deserve more focused
examination in future trials of GLN supplementation in
the ICU.
A number of other systematic reviews of GLN
supplementation in either much broader populations,
including noncritically ill patients, or specific populations(pancreatitis, burn injury, or elective surgery) have been
published recently [11-14]. To our knowledge, our sys-
tematic analysis is the first to focus on the parenteral use
of GLN supplementation of standard nutrition support in
which all subjects are critically ill. When compared to the
largest recent meta-analysis in a broader mixed elective
surgery and critical care population many similarities with
our data are observed [11]. First, with regard to mortality
this recent analysis of GLN showed a very similar trend
towards reduction of mortality (RR = 0.89; 95% CI, 0.77 to
1.04 versus RR 0.88, 95% CI 0.75, 1.03, in our analysis) in
a patient population with a lower illness severity (where
an effect on mortality would be less likely to be observed).
No analysis of hospital mortality was reported in this
previous analysis. With regard to infectious morbidity, this
earlier meta-analysis showed a stronger statistically signifi-
cant reduction of infectious morbidity (RR = 0.83; 95% CI,
0.72 to 0.95) compared to our data where a nonsignificant
trend of similar magnitude for a benefit on infection was
observed (RR 0.86, 95% CI 0.73, 1.02). Both the previous
and current systematic reviews reported significant reduc-
tions on hospital LOSs of approximately 2.5 days (−2.35;
95%, −3.68 to −1.02 versus −2.56, 95% CI −4.71, −0.42 in
our analysis). Other key differences of our analysis versus
the earlier report was that no direct industry funding was
involved in support of our analysis (partial funding by an
unrestricted industry grant was used to support this
previous analysis), we included all of the world literature
(including non-English trials) in our search, and we
successfully attempted in all cases to contact the original
authors when any questions of missing data or actual ICU
patient inclusion was in question. For the first time we
also examined the effect of GLN supplementation on
VAP. We were also able to incorporate original source
data from the unpublished multi-center American ‘GLND’
trial of GLN-supplementation of PN published in abstract
form [44]. Finally, we performed funnel plots for all
primary and key secondary endpoints examined by this
analysis to examine possible publication bias associated
with these endpoints.
The strength of our meta-analysis includes the use of
several methods to reduce bias (comprehensive literature
search, duplicate data abstraction, specific criteria for
searching and analysis) and focus on clinically important
primary outcomes. Notwithstanding, we are aware that
our meta-analysis has several limitations. The major
limitation is the small number of trials included in
certain subgroup analyses such as PN-supplementation
of EN. We also unfortunately could not perform sub-
group analysis for all endpoints due to limited numbers
of trials examining the particular endpoints. Another
potential weakness of any systematic review of random-
ized controlled nutrition trials has been pointed out by
Vincent et al. recently [48]. This is the potential inability
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conditions in the controlled setting of a trial (that is due
to many patient exclusions). That said, we feel this
systematic review best reflects all existing data in a wide
variety of critical care settings of parenteral GLN supple-
mentation to provide clinicians with most complete data
to assist in making clinical decisions. Further, despite
our attempts to be fully comprehensive in our search for
all available trials we may not have been to include all
available trials.
In spite of these limitations, we have demonstrated
that traditional GLN supplementation used in the con-
text of standard (predominantly parenteral) nutrition
support in the critically ill may significantly reduce
hospital mortality and shorten hospital LOS with a trend
towards reduction in overall mortality and infectious
complications, including VAP, and ICU LOS. Nonetheless,
many questions on the ideal dose and timing of GLN sup-
plementation in the ICU still remain unanswered. Further
research is warranted to define the optimal dose and
timing of supplementation of GLN in patients receiving
full nutrition support. Recent data from REDOXS and
other trials suggest that parenteral GLN should not be
given in patients early in the acute phase of critical illness,
in patients with multiple organ failure or in patients with
unresuscitated shock requiring significant vasopressor
support. Finally, based on the results of the REDOXS
trial [6], we believe that high-dose parenteral or par-
enteral + enteral GLN (doses >0.5 g/kg/d) should not
be used during the acute phase of critical illness.
Conclusions
In this comprehensive systematic review, we demonstrate
that traditional parenteral GLN supplementation as a
component of nutrition support (primarily added to PN)
is associated with a significant decrease in hospital mortal-
ity and length of hospital stay. GLN supplementation is
also associated with trends towards reduced overall mor-
tality, infectious complications and ICU LOS in critically
ill patients. The therapeutic effect may be dependent on
GLN dose given, with optimal benefit traditionally obser-
ved between 0.3 and 0.5 g/kg/d. Thus, we recommend
that parenteral GLN supplementation as a component of
nutrition support be considered as an approach to im-
prove outcomes of critical illness in selected patients. Our
data here suggest that parenteral GLN supplementation,
as a component of complete PN and/or EN support, is
safe when administered following resolution of shock and
multi-organ failure, and with daily doses less the 0.5 g/kg/d.
Focused clinical trials on the clinical efficacy of paren-
teral GLN supplementation combined with adequate and
complete specialized nutrition support are needed in
critically ill patients at risk of GLN depletion who do
not have multiple organ failure or ongoing shock.Key messages
 Critical illness is characterized by severe metabolic
stress and glutamine depletion has been associated
with increased mortality in some recent studies.
In this context, supplementation of parenteral
glutamine, predominantly as a component of
parenteral nutrition, may improve clinical outcomes
when given to appropriate patients as part of
complete nutrition support.
 Supplemental parenteral glutamine may significantly
decrease hospital mortality and shorten hospital
LOS in critically ill patients.
 Supplemental parenteral glutamine given as a
component of nutrition support is associated
with a trend towards a reduction in overall
mortality, infectious morbidity, and ICU LOS in
critically ill patients.
 We suggest supplemental glutamine should not be
given in a high dose (>0.5 g/kg/day) or in patients
early in the acute phase of critical illness in patients
with multiple organ failure or unresuscitated shock
requiring significant vasopressor support.
 When parenteral nutrition is prescribed to critically
ill patients, parenteral supplementation with
glutamine should continue to be considered safe
and may potentially improve outcomes in the ICU
in patients without specific contraindications.
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